MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.810
-0.140
-3.54%
After Hours: 3.700 -0.11 -2.89% 17:50 01/21 EST
OPEN
3.920
PREV CLOSE
3.950
HIGH
4.005
LOW
3.810
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
10.09
52 WEEK LOW
3.810
MARKET CAP
298.07M
P/E (TTM)
-5.4096
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 5d ago
Viking Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase
Benzinga · 01/10 12:04
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will d...
PR Newswire · 01/03 12:30
Viking Therapeutics, Inc. (NASDAQ:VKTX) insider upped their holding by 43% earlier this year
From what we can see, insiders were net buyers in Viking Therapeutics, Inc.'s ( NASDAQ:VKTX ) during the past 12...
Simply Wall St. · 12/28/2021 14:40
Viking Therapeutics Granted U.S. Patent #11,202,789 'Method of treating glycogen storage disease'
View patent here
Benzinga · 12/21/2021 13:21
uniQure (QURE) Falls on Data From Huntington's Disease Study
uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.
Zacks · 12/17/2021 15:06
Calliditas' (CALT) Tarpeyo Wins FDA Approval for Renal Disease
Zacks.com · 12/16/2021 14:26
Foghorn (FHTX) Surges on Oncology Collaboration With Lilly
Zacks.com · 12/14/2021 15:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VKTX stock price target is 20.67 with a high estimate of 40.00 and a low estimate of 12.00.
High40.00
Average20.67
Low12.00
Current 3.810
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 223
Institutional Holdings: 44.13M
% Owned: 56.40%
Shares Outstanding: 78.23M
TypeInstitutionsShares
Increased
40
2.24M
New
9
169.74K
Decreased
47
2.24M
Sold Out
12
276.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Non-Executive Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Chief Financial Officer/IR Contact Officer
Greg Zante
Chief Operating Officer
Marianne Mancini
Director
Matthew Foehr
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
J. Matthew Singleton
No Data
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.